RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached “Database Lock”. This means that all data from the trial is now finally reported, cleaned and “locked” in the data base. The next step will be analysis to produce the results. As previously stated, RhoVac anticipates having its primary results no later than at the beginning of June.RhoVac started the clinical phase IIb trial (BRaVac) with the company’s drug candidate, RV001, (onilcamotide) late 2019, in prostate cancer patients